Glioma This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog.Subscribe to this data using Feedly.
This page shows you the latest news and research items in this category.
Glioma-specific Domain IV EGFR cysteine mutations promote ligand-induced covalent receptor dimerization and display enhanced sensitivity to dacomitinib in vivo.
p; T E Adams (Source: Oncogene)
Source: Oncogene - April 21, 2014 Category: Cancer & Oncology Authors: S A GreenallJ F DonoghueN G GottardoT G JohnsT E Adams Source Type: research
Antitumor effect of fibrin glue containing temozolomide against malignant glioma
Temozolomide (TMZ), used to treat glioblastoma and malignant glioma, induces autophagy, apoptosis and senescence in cancer cells. We investigated fibrin glue (FG) as a drug delivery system for the local administration of high‐concentration TMZ aimed at preventing glioma recurrence. Our high‐power liquid chromatography studies indicated that FG containing TMZ (TMZ‐FG) manifested a sustained drug release potential. We prepared a subcutaneous tumor model by injecting groups of mice with three malignant glioma cell lines and examined the antitumor effect of TMZ‐FG. We estimated the tumor volume and performed immunostai...
Source: Cancer Science - April 19, 2014 Category: Cancer & Oncology Authors: Shigeo Anai, Takuichiro Hide, Tatsuya Takezaki, Jun‐ichiro Kuroda, Naoki Shinojima, Keishi Makino, Hideo Nakamura, Shigetoshi Yano, Jun‐ichi Kuratsu Tags: Original Article Source Type: research
Differential expression of microRNA-210 in gliomas of variable cell origin and correlation between increased expression levels and disease progression in astrocytic tumours.
Conclusions: MiR-210 levels can be potentially established as a biomarker for pathological diagnosis of malignant astrocytic tumour progression. In addition, the expression of miR-210 can be utilized as an additional identification measure of glioma tumour origin. PMID: 24729345 [PubMed - in process] (Source: Folia Neuropathologica)
Source: Folia Neuropathologica - April 18, 2014 Category: Pathology Authors: Lai N, Zhu H, Chen Y, Zhang S, Zhao X, Lin Y Tags: Folia Neuropathol Source Type: research
Coinhibitory receptor PD-1H preferentially suppresses CD4+ T cell–mediated immunity
T cell activation is regulated by the interactions of surface receptors with stimulatory and inhibitory ligands. Programmed death-1 homolog (PD-1H, also called VISTA) is a member of the CD28 family of proteins and has been shown to act as a coinhibitory ligand on APCs that suppress T cell responses. Here, we determined that PD-1H functions as a coinhibitory receptor for CD4+ T cells. CD4+ T cells in mice lacking PD-1H exhibited a dramatically increased response to antigen stimulation. Furthermore, delivery of a PD-1H–specific agonist mAb directly inhibited CD4+ T cell activation both in vitro and in vivo, validating a co...
Source: Journal of Clinical Investigation - April 18, 2014 Category: Biomedical Science Authors: Dallas B. Flies, Xue Han, Tomoe Higuchi, Linghua Zheng, Jingwei Sun, Jessica Jane Ye, Lieping Chen Source Type: research
Glioma associated microglial MMP9 expression is up regulated by TLR2 signalling and sensitive to minocycline
Abstract The invasiveness of malignant gliomas is one of the major obstacles in glioma therapy and the reason for the poor survival of patients. Glioma cells infiltrate into the brain parenchyma and thereby escape surgical resection. Glioma associated microglia/macrophages support glioma infiltration into the brain parenchyma by increased expression and activation of extracellular matrix degrading proteases such as matrix‐metalloprotease 2, matrix‐metalloprotease 9 and membrane‐type 1 matrix metalloprotease. In this work we demonstrate that, matrix‐metalloprotease 9 is predominantly expressed by glioma associated m...
Source: International Journal of Cancer - April 18, 2014 Category: Cancer & Oncology Authors: Feng Hu, Min‐Chi Ku, Darko Markovic, Omar Dildar a Dzaye, Seija Lehnardt, Michael Synowitz, Susanne A. Wolf, Helmut Kettenmann Tags: Cancer Cell Biology Source Type: research
The left inferior fronto-occipital fasciculus subserves language semantics: a multilevel lesion study.
Abstract Consequential works in cognitive neuroscience have led to the formulation of an interactive dual-stream model of language processing: the dorsal stream may process the phonological aspects of language, whereas the ventral stream may process the semantic aspects of language. While it is well-accepted that the dorsal route is subserved by the arcuate fasciculus, the structural connectivity of the semantic ventral stream is a matter of dispute. Here we designed a longitudinal study to gain new insights into this central but controversial question. Thirty-one patients harboring a left diffuse low-grade glioma-...
Source: Brain Structure and Function - April 18, 2014 Category: Neuroscience Authors: Almairac F, Herbet G, Moritz-Gasser S, de Champfleur NM, Duffau H Tags: Brain Struct Funct Source Type: research
Gender as a disease modifier in neurofibromatosis type 1 optic pathway glioma
(Source: Annals of Neurology)
Source: Annals of Neurology - April 17, 2014 Category: Neurology Authors: Michael J. Fisher, Michael Loguidice, David H. Gutmann, Robert Listernick, Rosalie E. Ferner, Nicole J. Ullrich, Roger J. Packer, Uri Tabori, Robert O. Hoffman, Simone L. Ardern‐Holmes, Trent R. Hummel, Darren R. Hargrave, Eric Bouffet, Joel Charrow, La Tags: Letter to the Editor Source Type: research
Prolongation of Life in Rats with Malignant Glioma
by Intranasal siRNA/Drug Codelivery to the Brain with Cell-Penetrating
Molecular PharmaceuticsDOI: 10.1021/mp400644e (Source: Molecular Pharmaceutics)
Source: Molecular Pharmaceutics - April 16, 2014 Category: Drugs & Pharmacology Authors: Takanori Kanazawa, Kazuki Morisaki, Shohei Suzuki and Yuuki Takashima Source Type: research
ERGO: A pilot study of ketogenic diet in recurrent glioblastoma.
In conclusion, a ketogenic diet is feasible and safe but probably has no significant clinical activity when used as single agent in recurrent glioma. Further clinical trials are necessary to clarify whether calorie restriction or the combination with other therapeutic modalities, such as radiotherapy or anti-angiogenic treatments, could enhance the efficacy of the ketogenic diet. PMID: 24728273 [PubMed - in process] (Source: International Journal of Oncology)
Source: International Journal of Oncology - April 16, 2014 Category: Cancer & Oncology Authors: Rieger J, Bähr O, Maurer GD, Hattingen E, Franz K, Brucker D, Walenta S, Kämmerer U, Coy JF, Weller M, Steinbach JP Tags: Int J Oncol Source Type: research
Combination of MRI and dynamic FET PET for initial glioma grading.
Conclusion: Combination of dynamic FET-PET and diffusion MRI reached good performance for gliomas grading. The use of FET-PET/MR may be highly relevant in the initial assessment of primary brain tumours. PMID: 24737132 [PubMed - as supplied by publisher] (Source: Nuklearmedizin)
Source: Nuklearmedizin - April 16, 2014 Category: Radiology Authors: Dunet V, Maeder P, Nicod-Lalonde M, Lhermitte B, Pollo C, Bloch J, Stupp R, Meuli R, Prior JO Tags: Nuklearmedizin Source Type: research
Tetrandrine and Caffeine Modulated Cell Cycle and Increased Glioma Cell Death via Caspase-Dependent and Caspase-Independent Apoptosis Pathways.
In conclusion, tetrandrine and caffeine could induce glioma cell death possibly via increasing eIF-2α phospharylation, decreasing cyclin-D1 expression, and increasing caspase-dependent and -independent apoptosis pathways. PMID: 24738643 [PubMed - as supplied by publisher] (Source: Nutrition and Cancer)
Source: Nutrition and Cancer - April 16, 2014 Category: Cancer & Oncology Authors: Chen JC, Hwang JH, Chiu WH, Chan YC Tags: Nutr Cancer Source Type: research
Rapid‐Steady‐State‐T1 signal modeling during contrast agent extravasation: Toward tumor blood volume quantification without requiring the arterial input function
ConclusionStraightforward tumor BVf quantification without AIF determination is demonstrated in presence of CA leakage. The method will facilitate angiogenesis assessment in longitudinal neuro‐oncologic studies in particular when monitoring the response to antiangiogenic therapies. Magn Reson Med, 2014. © 2014 Wiley Periodicals, Inc. (Source: Magnetic Resonance in Medicine)
Source: Magnetic Resonance in Medicine - April 14, 2014 Category: Radiology Authors: Michel Sarraf, Adriana Teodora Perles‐Barbacaru, Marie France Nissou, Boudewijn Sanden, François Berger, Hana Lahrech Tags: Full Paper Source Type: research
Rapid-Steady-State-T1 signal modeling during contrast agent extravasation: Toward tumor blood volume quantification without requiring the arterial input function.
CONCLUSION: Straightforward tumor BVf quantification without AIF determination is demonstrated in presence of CA leakage. The method will facilitate angiogenesis assessment in longitudinal neuro-oncologic studies in particular when monitoring the response to antiangiogenic therapies. Magn Reson Med, 2014. © 2014 Wiley Periodicals, Inc. PMID: 24733739 [PubMed - as supplied by publisher] (Source: Magnetic Resonance in Medicine)
Source: Magnetic Resonance in Medicine - April 14, 2014 Category: Radiology Authors: Sarraf M, Perles-Barbacaru AT, Nissou MF, van der Sanden B, Berger F, Lahrech H Tags: Magn Reson Med Source Type: research
Nanoparticles functionalized with Pep-1 as potential glioma targeting delivery system via interleukin 13 receptor α2-mediated endocytosis.
In conclusion, the Pep-NP could precisely target to the brain glioma, which was a potential targeting drug delivery system for glioma treatment. PMID: 24743033 [PubMed - as supplied by publisher] (Source: Biomaterials)
Source: Biomaterials - April 14, 2014 Category: Materials Science Authors: Wang B, Lv L, Wang Z, Zhao Y, Wu L, Fang X, Xu Q, Xin H Tags: Biomaterials Source Type: research
The impact of a chlorotoxin-modified liposome system on receptor MMP-2 and the receptor-associated protein ClC-3.
Abstract Currently, it is unknown whether a receptor-associated protein will be affected when a ligand modified delivery system interacts with its receptor. Besides, chlorotoxin (ClTx)-modified liposomes can target to glioma cells, but the target molecule is not clear: MMP-2, ClC-3 or both? Here a comparative study of ClTx-conjugated liposomes was conducted on two types of tumor cells: U87, a human glioma cell line with high expression of both MMP-2 and ClC-3, and A549, a human lung cancer cell line with expression of only MMP-2. ClTx-modified liposomes behaved similarly in these two cancer cells in terms of in vi...
Source: Biomaterials - April 14, 2014 Category: Materials Science Authors: Qin C, He B, Dai W, Lin Z, Zhang H, Wang X, Wang J, Zhang X, Wang G, Yin L, Zhang Q Tags: Biomaterials Source Type: research
Targeting gallbladder cancer: oncolytic virotherapy with myxoma virus is enhanced by rapamycin in vitro and further improved by hyaluronan in vivo
Conclusions: Unlike MYXV + Rap, MYXV + HA therapy significantly enhanced the anti-tumor effects of MYXV in vivo and prolonged survival of GBC tumor-bearing mice. HA may optimize the oncolytic effects of MYXV on GBC via the HA-CD44 interaction which can promote viral infection and diffusion. (Source: Epidemiologic Perspectives and Innovations)
Source: Epidemiologic Perspectives and Innovations - April 13, 2014 Category: Epidemiology Authors: Mingzhe WengGong WeiMingzhe MaBingfeng ChuYiyu QinMingdi ZhangXueqing LunGrant McFaddenPeter ForsythYong YangZhiwei Quan Source Type: research
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
Conclusion: This is the first report of a complete response of relapsed glioblastoma multiforme to targeted BRAF inhibitor therapy. While not a predominant mutation in glioblastoma multiforme, the increased prevalence of BRAF V600 mutations in pediatric CNS tumors and certain subtypes marks a population to whom this therapy could be applied. Response to this therapy suggests that BRAF inhibitors can affect primary CNS lesions when a documented and targetable mutation is present. (Source: BMC Cancer)
Source: BMC Cancer - April 12, 2014 Category: Cancer & Oncology Authors: Giles RobinsonBrent OrrAmar Gajjar Source Type: research
Triptolide Synergistically Enhances Temozolomide-Induced Apoptosis and Potentiates Inhibition of NF-κB Signaling in Glioma Initiating Cells.
In this study, we explored the interaction of TPL and TMZ in glioma-initiating cells (GICs) and the potential mechanism. A GIC line (GIC-1) was successfully established. Cell viability of GIC-1 after treatment was measured using a CCK-8 assay. The interaction between TPL and TMZ was calculated from Chou-Talalay equations and isobologram. Self-renewal was evaluated with tumor sphere formation assay. Apoptosis was assessed with flow cytometry and western blot. Luciferase assay was employed to measure NF-κB transcriptional activity. The expression of NF-κB downstream genes, NF-κB nuclear translocalization and phoshorylatio...
Source: The American Journal of Chinese Medicine - April 11, 2014 Category: Complementary Medicine Authors: Sai K, Li WY, Chen YS, Wang J, Guan S, Yang QY, Guo CC, Mou YG, Li WP, Chen ZP Tags: Am J Chin Med Source Type: research
Therapeutic concentration of morphine reduces oxidative stress in glioma cell line.
This study supports the importance of employing concentrations similar to those used in clinical practice for a better approximation between experimental models and the clinical setting. PMID: 24728211 [PubMed - as supplied by publisher] (Source: Braz J Med Biol Res)
Source: Braz J Med Biol Res - April 11, 2014 Category: Research Authors: Almeida MB, Costa-Malaquias A, Nascimento JL, Oliveira KR, Herculano AM, Crespo-López ME Tags: Braz J Med Biol Res Source Type: research
Cetuximab Induces Eme1-Mediated DNA Repair: a Novel Mechanism for Cetuximab Resistance.
Abstract Overexpression of the epidermal growth factor receptor (EGFR) is observed in a large number of neoplasms. The monoclonal antibody cetuximab/Erbitux is frequently applied to treat EGFR-expressing tumors. However, the application of cetuximab alone or in combination with radio- and/or chemotherapy often yields only little benefit for patients. In the present study, we describe a mechanism that explains resistance of both tumor cell lines and cultured primary human glioma cells to cetuximab. Treatment of these cells with cetuximab promoted DNA synthesis in the absence of increased proliferation, suggesting th...
Source: Neoplasia - April 11, 2014 Category: Cancer & Oncology Authors: Weinandy A, Piroth MD, Goswami A, Nolte K, Sellhaus B, Gerardo-Nava J, Eble M, Weinandy S, Cornelissen C, Clusmann H, Lüscher B, Weis J Tags: Neoplasia Source Type: research
Craniopharyngeal Canal and Its Spectrum of Pathology [HEAD & NECK]
CONCLUSIONS: Accurate diagnosis and classification of craniopharyngeal canals are valuable to characterize lesions requiring surgery, identify patients with potential pituitary dysfunction, and avoid iatrogenic hypopituitarism or CSF leak during surgical resection of nasopharyngeal masses. (Source: American Journal of Neuroradiology)
Source: American Journal of Neuroradiology - April 10, 2014 Category: Radiology Authors: Abele, T. A., Salzman, K. L., Harnsberger, H. R., Glastonbury, C. M. Tags: HEAD & amp; NECK Source Type: research
Internet-based guided self-help for glioma patients with depressive symptoms: design of a randomized controlled trial
DiscussionThis is the first study to evaluate the effects of problem-solving therapy delivered through the internet as treatment for depressive symptoms in glioma patients. If proven effective, this treatment will contribute to the mental health care of glioma patients in clinical practice.Trial registration: Netherlands Trial Register NTR3223 (Source: BMC Neurology)
Source: BMC Neurology - April 10, 2014 Category: Neurology Authors: Florien BoeleIrma LeeuwPim CuijpersJaap ReijneveldJan HeimansMartin Klein Source Type: research
OASIS regulates chondroitin 6‐O‐sulfotransferase 1 gene transcription in the injured adult mouse cerebral cortex
This article is protected by copyright. All rights reserved. (Source: Journal of Neurochemistry)
Source: Journal of Neurochemistry - April 9, 2014 Category: Neurology Authors: Hiroaki Okuda, Kouko Tatsumi, Noriko Horii‐Hayashi, Shoko Morita, Aya Okuda‐Yamamoto, Kazunori Imaizumi, Akio Wanaka Tags: Original Article Source Type: research
Inflammatory Cerebral Amyloid Angiopathy Mimicking an Aggressive Glioma (P2.104)
CONCLUSIONS: This case exemplifies the wide clinical spectrum seen in CAA, our patient’s rapidly progressive neurologic decline was due to CAA-I. The MRI findings were highly suggestive of an infiltrative tumor though asymmetric and confluent white matter hyperintensities can also be seen in CAA-I. The use of susceptibility weighted imaging sequences on brain MRI increases sensitivity for the diagnosis of cerebral microbleeds over other sequences and should be utilized to differentiate CAA-I from other infectious, inflammatory and malignant etiologies. The recognition of CAA-I is critical as the response to immunothe...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Reynolds, A., Byrd, E., Davis, A., Mossa-Basha, M., Khot, S. Tags: Cerebrovascular Disease and Interventional Neurology: Acquired and Congenital Vascular Malformations Source Type: research
Characterization Of Seizures And Their Response To Treatment In a Cohort Of Patients With Glial Tumors In a University Institute (P3.312)
ConclusionsA meticulous examination of the patient and family/ witnesses allows a better diagnosis and characterization of epileptic seizures and the possibility of withdrawing treatment in seizure-free patients. Twenty six percent of patients referred with "convulsive seizures" were reclassified as partial seizures. Partial seizures are the most common type in patients with glial tumors. Levetiracetam used as monotherapy is suitable for these patientsDisclosure: Dr. Tafur Canabal has nothing to disclose. Dr. Gonzalez Roffo has nothing to disclose. Dr. Kuchkaryan has nothing to disclose. Dr. Campanucci has nothing to discl...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Tafur Canabal, J., Gonzalez Roffo, A., Kuchkaryan, V. B., Campanucci, V., Igirio Gamero, J., Baez, A., Sanchez Retamar, C., Casas Parera, I. Tags: Neurologic Complications of Cancer Source Type: research
Glioblastoma Multiforme in a Patient with Multiple Sclerosis: A Case Report (P3.324)
Conclusions: Genetic characterization of gliomas in patients with MS has failed to establish unique abnormalities that could account for secondary malignant transformation of glial cells. Fingolimod has antineoplastic capacity by means of down regulation in the expression of S1PRs which in turn decreases production of S1P by sphingosine kinase. Currently there is no strong evidence to support an increased risk of developing cancer in MS patients. Treatment with fingolimod confers a theoretical decreased risk of developing gliomas. Further studies are needed to increase our understanding of this singular presentation.Disclo...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Romo, C., Herlopian, A., Chauhan, N., Archer, R., Ong, S. Tags: Neuro-oncology: Paraneoplastic Syndromes and Other Antibody-Mediated Disorders Source Type: research
Distinguishing Clinico-Radiological Features in Patients with Central Nervous System Tumefactive White Matter Lesions (P5.177)
CONCLUSIONSTumefactive DD WML tend to be smaller, discrete, periventricular with less peripheral rim enhancement and mass effect. Laboratory tests but not presenting symptoms may also aid in distinguishing DD from CNS tumours.Disclosure: Dr. Lin has nothing to disclose. Dr. Liauw has nothing to disclose. Dr. Tin has nothing to disclose. Dr. Soon has nothing to disclose. Dr. Yin Shih, Raphael has nothing to disclose. Dr. Toe has nothing to disclose. Dr. Lee has nothing to disclose. Dr. Yu has nothing to disclose. (Source: Neurology)
Source: Neurology - April 9, 2014 Category: Neurology Authors: Lin, X., Tan, K., Liauw, L., Tin, A. S., Soon, W. E., Yin Shih, Raphael, Z., Toe, B. P., Lee, H. Y., Yu, W.-Y. Tags: CNS Diseases and Differential Diagnosis Source Type: research
Bradycardia Leading To Pacemaker Placement: A Characteristic Prodromal Syndrome Of VGKCC/LGI1 Antibody Associated Encephalitis (P5.195)
CONCLUSIONS: Acute bradycardia with associated heightened emotionality is a distinctive prodromal, possibly epileptic, syndrome of VGKCC/LGI1-encephalitis. The neuroanatomical localization most likely relates to insular involvement, a cortical area involved in cardiac autonomic regulation. Whether earlier diagnosis and initiation of immunosuppresion at the time of the neurocardiac prodrome will help to prevent progression to encephalopathy, as has been proposed for FBDS, remains to be determined.Disclosure: Dr. Naasan has nothing to disclose. Dr. Irani has received royalty payments. Dr. Bettcher has nothing to disclose. Dr...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Naasan, G., Irani, S., Bettcher, B., Geschwind, M., Gelfand, J. Tags: CNS Diseases and Differential Diagnosis Source Type: research
"Pseudostroke": Clinically Diagnosed Ischemia Shown to Be Multiple Sclerosis at Autopsy, A Case Report (P6.266)
CONCLUSIONS:This case emphasizes the difficult clinical and neuroradiological differential between acute stroke and acute MS in a patient presenting with new neurologic deficits with sudden onset. It appears that ADC in very acute lesions of MS may show low signal, contrary to the usual expectations. The high ADC signal reflects the increased extracellular space produced by extracellular edema or demyelination. Acute MS lesions can thus present as "Pseudostrokes".Disclosure: Dr. Uppal has nothing to disclose. Dr. Kataria has nothing to disclose. Dr. Rani has nothing to disclose. Dr. Miller has nothing to disclose. (Source: Neurology)
Source: Neurology - April 9, 2014 Category: Neurology Authors: Uppal, G., Kataria, N., Rani, P., Miller, D. Tags: Cerebrovascular Disease and Interventional Neurology: Case Reports Source Type: research
Functional Expression of K2P Potassium Channels in Tumor Infiltrating Lymphocytes of Malignant Glioma (P7.012)
CONCLUSIONS: K2P ion channels clearly play a role in local tumor control, as knockout mice exhibit a delayed onset of symptoms and a longer survival after tumor implantation. This is not caused by altered expression profiles of K2P ion channels as compared to wildtype mice, but may be caused by changed infiltration patterns, thus leading to improved local tumor control. The mechanisms of these effects and the role of other K2P channels are currently under investigation.Study Supported by:Disclosure: Dr. Simon has received personal compensation for activities with Biogen Idec. Dr. Muentefering has nothing to disclose. Dr. B...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Simon, O., Muentefering, T., Bittner, S., Melzer, N., Wiendl, H., Grauer, O., Meuth, S. Tags: Neuro-oncology Source Type: research
Isolated Primary CNS Infiltrative Parenchymal Histiocytosis with Intraventricular Hemorrhage (P7.256)
CONCLUSIONS:We present a unique case of primary CNS parenchymal infiltrative with full systemic, CSF, MRI and pathologic descriptions, not meeting criteria for other described histiocytic disorders known to affect the CNS.Disclosure: Dr. Mittelmann has nothing to disclose. Dr. Lasala has nothing to disclose. Dr. Weidenheim has nothing to disclose. Dr. Graber has received personal compensation for activities with Stemedica Inc., Novocure Inc., and Biogen Idec. (Source: Neurology)
Source: Neurology - April 9, 2014 Category: Neurology Authors: Mittelmann, E., LaSala, P., Weidenheim, K., Graber, J. Tags: Neuro-oncology: CNS Metastases and Complications of Treatment Source Type: research
Brainstem Glioma 8 Years After External Beam Radiotherapy for Pituitary Macroadenoma: Correlation with Radiation Treatment Dose and Volume (P7.257)
CONCLUSIONS: The rare occurrence of brainstem RAG after radiation therapy for pituitary tumors supports the need for long-term imaging monitoring of such patients.Disclosure: Dr. Abboud has nothing to disclose. Dr. Wolansky has nothing to disclose. Dr. Manjila has nothing to disclose. Dr. Lo has nothing to disclose. Dr. Arafah has nothing to disclose. Dr. Rogers has received personal compensation for activities with Sigma Tau Pharmaceuticals. (Source: Neurology)
Source: Neurology - April 9, 2014 Category: Neurology Authors: Abboud, S., Wolansky, L., Manjila, S., Lo, S., Arafah, B., Selman, W., Rogers, L. Tags: Neuro-oncology: CNS Metastases and Complications of Treatment Source Type: research
Hormone Replacement Therapy and Risk of Glioma: A Nationwide Nested Case-Control Study (P7.266)
Conclusion:Use of HRT overall was not associated with an increased risk of glioma. However, our findings indicate that prolonged use of oestrogen only or progestagen may be associated with an increased risk of glioma.Study supported by:This study was supported by grants from the Danish Cancer Society (grant nr. R56-A2879), Odense University Hospital, the Region of Southern Denmark, and the University of Southern Denmark. The funding sources had no role in the design, analysis, and interpretation of the results.Disclosure: Dr. Andersen has nothing to disclose. Dr. Friis has nothing to disclose. Dr. Hallas has received perso...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Andersen, L., Friis, S., Hallas, J., Ravn, P., Gaist, D. Tags: Neuro-oncology: Primary CNS Tumors: Gliomas Source Type: research
Relationship between CD44v6 and E-cadherin Expression in Human Primary Brain Tumors (P7.267)
CONCLUSIONS:Our findings indicate that association between E-cadherin and CD44v6 expression may facilitate the migration of tumor cells from the primary tumor to surrounding tissue and promote invasive growth of gliomas.Disclosure: Dr. Zub has nothing to disclose. Dr. Paradowski has nothing to disclose. Dr. Paradowski has nothing to disclose. Dr. Lis-Nawara has nothing to disclose. Dr. Noga has nothing to disclose. Dr. Jelen has nothing to disclose. (Source: Neurology)
Source: Neurology - April 9, 2014 Category: Neurology Authors: Zub, L., Paradowski, B., Bar, J., Lis-Nawara, A., Noga, L., Jelen, M. Tags: Neuro-oncology: Primary CNS Tumors: Gliomas Source Type: research
A Novel Therapeutic Target for Treatment of Malignant Brain Tumors (P7.268)
Conclusions: The gene critical for the de novo GTP synthesis pathway is overexpressed in malignant brain tumors. Since MMF is an FDA approved drug with anti-tumor effects in a number of solid and blood cancers, it has immense potential for treatment of malignancies that overexpress IMPDH including glioblstoma.Disclosure: Dr. Majd has nothing to disclose. Dr. Sumita has nothing to disclose. Dr. Yoshino has nothing to disclose. Dr. Chen has nothing to disclose. Dr. Sasaki has nothing to disclose. (Source: Neurology)
Source: Neurology - April 9, 2014 Category: Neurology Authors: Majd, N., Sumita, K., Yoshino, H., Chen, D., Sasaki, A. Tags: Neuro-oncology: Primary CNS Tumors: Gliomas Source Type: research
Posterior Fossa Recurrences Of Supratentorial WHO Grade II and III Gliomas (P7.269)
CONCLUSIONS:PF relapse of ST gr II-III gliomas is rare and occur mainly in oligodendroglial tumors. It may be the first manifestation of a widespread parenchymal dissemination with a dismal prognosis. However, PF involvement remains isolated in about half the patients (particularly low grade gliomas and some O III), with a good response to focal RT and long term survival. The mechanisms of this singular tropism is unknown but subependymal spread is suspected.Study Supported by:Disclosure: Dr. Terziev has nothing to disclose. Dr. Petrirena has nothing to disclose. Dr. Delattre has nothing to disclose. (Source: Neurology)
Source: Neurology - April 9, 2014 Category: Neurology Authors: Terziev, R., Petrirena, G., Delattre, J.-Y. Tags: Neuro-oncology: Primary CNS Tumors: Gliomas Source Type: research
Posterior Fossa Tumours in Children as Seen in a Tertiary and Referral Hospital in Sub-Saharan Africa (P7.270)
Conclusion: Posterior cranial fossa tumours in our set- up are more common in males than females. Most cases of medulloblastomas are found among female children. The delay in diagnosis and definitive management is noted probably due to lack of awareness and expensive modalities of management.Disclosure: Dr. Kwasi has nothing to disclose. (Source: Neurology)
Source: Neurology - April 9, 2014 Category: Neurology Authors: Kwasi, V. Tags: Neuro-oncology: Primary CNS Tumors: Gliomas Source Type: research
Oligodendroglial Gliomatosis Cerebri Exhibiting Leptomeningeal And Nerve Root Involvement (P7.271)
Conclusions:In the context of gliomatosis cerebri, the extent and infiltrative pattern, the positive CSF cytology and the histological subtype, make this case highly unusual. The lack of specific findings both clinically and on imaging, despite the level of neoplastic infiltration seen post-mortem, highlight the diagnostic challenge this neoplasm presents.Disclosure: Dr. Mcmacken has nothing to disclose. Dr. Herron has nothing to disclose. Dr. Fulton has nothing to disclose. (Source: Neurology)
Source: Neurology - April 9, 2014 Category: Neurology Authors: Mcmacken, G., Herron, B., Fulton, A. Tags: Neuro-oncology: Primary CNS Tumors: Gliomas Source Type: research
A Case Report: Primary Glioblastoma of the Pineal (P7.272)
Conclusion:Based on a literature review, since the 1972 report of Bradfield and Perez, only 18 cases were reported, not including the one described here. A SEERs database review showed 9 registered cases of WHO Grade IV gliomas from 1973-2005. As with our patient, symptoms related to hydrocephalus and Parinaud’s syndrome tend to be the most common presentation. Imaging modalities such as CT and contrast MRI imaging is important in the initial evaluation of the patient, final diagnosis is made on histologic basis. Albeit extremely rare in the pineal region, this case along with others previously described, continues t...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Krel, R., Krutoshinskaya, Y., Rosiello, A., Seidman, R., Kowalska, A. Tags: Neuro-oncology: Primary CNS Tumors: Gliomas Source Type: research
Aggressive Medical Care at the End of Life (EOL) in Glioblastoma (GBM): The 5-year Memorial Sloan-Kettering Cancer Center (MSKCC) Experience (P7.273)
CONCLUSIONS:In our population one fifth of GBM patients received aggressive care at the EOL. Predictors of this pattern of treatment and its association with outcomes such as quality of life require further study.Disclosure: Dr. Dallara has nothing to disclose. Dr. Carver has nothing to disclose. Dr. Diamond has nothing to disclose. (Source: Neurology)
Source: Neurology - April 9, 2014 Category: Neurology Authors: Dallara, A., Carver, A., Diamond, E. Tags: Neuro-oncology: Primary CNS Tumors: Gliomas Source Type: research
Neuro-oncology Telemedicine Follow-up Visits (P7.274)
CONCLUSIONS: These data suggest that neuro-oncology can be practiced safely and effectively using a telemedicine system, with high levels of patient satisfaction.Disclosure: Dr. Green has nothing to disclose. Dr. Woyshner has nothing to disclose. Dr. Hauser Dehaven has nothing to disclose. (Source: Neurology)
Source: Neurology - April 9, 2014 Category: Neurology Authors: Green, R., Woyshner, E., Hauser Dehaven, A. Tags: Neuro-oncology: Primary CNS Tumors: Gliomas Source Type: research
A Vaccine Targeting Mutant IDH1 Induces Antitumor Immunity (S22.001)
CONCLUSIONS: As IDH1R132H is an early mutation present in all tumor cells of most low grade and anaplastic gliomas, a mutation-specific anti-IDH1-vaccine represents a viable novel therapeutic strategy for IDH1R132H-mutated gliomas. The design of a phase I/II clinical trial is presented.Study Supported by: Disclosure: Dr. Platten has nothing to disclose. Dr. Schumacher has nothing to disclose. Dr. Bunse has nothing to disclose. Dr. Sahm has nothing to disclose. Dr. Pusch has nothing to disclose. Dr. Quandt has nothing to disclose. Dr. Menn has nothing to disclose. Dr. Osswald has nothing to disclose. Dr. Riemer has nothing ...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Platten, M., Schumacher, T., Bunse, L., Sahm, F., Pusch, S., Quandt, J., Menn, O., Osswald, M., Riemer, A., Beckhove, P., Friese, M. A., von Deimling, A., Wick, W. Tags: Neuro-oncology Source Type: research
The Neurologic Assessment in Neuro-Oncology (NANO) Scale: A Tool to Assess Neurologic Function for Integration in the Radiologic Assessment in Neuro-Oncology (RANO) Criteria (S22.005)
CONCLUSIONS: The NANO criteria provide a more detailed and objective measure of neurologic function than currently exists for brain tumor patients. These criteria enable a consistent evaluation of neurologic function that can be assessed across clinical trials and therapeutic interventions. Implementation and validation of these criteria are planned and will likely be regularly refined for further optimization.Disclosure: Dr. Nayak has nothing to disclose. Dr. DeAngelis has received personal compensation for activities with the NFL Players Association as a consultant. Dr. Wen has received personal compensation for activiti...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Nayak, L., DeAngelis, L., Wen, P., Brandes, A., Soffietti, R., Lin, N., Peereboom, D., Chamberlain, M., Macdonald, D., Galanis, E., Perry, J., Jaeckle, K., Mehta, M., Stupp, R., Van Den Bent, M., Reardon, D. Tags: Neuro-oncology Source Type: research
Multifunctional liposomes loaded with paclitaxel and artemether for treatment of invasive brain glioma.
Abstract Invasive brain glioma is the most lethal type of cancer and is highly infiltrating. This leads to an extremely poor prognosis and makes complete surgical removal of the tumor virtually impossible. Non-penetration of therapeutic drugs across the blood-brain barrier (BBB), brain cancer stem cells (CSCs), and brain cancer vasculogenic mimicry (VM) results in relapse after surgical and radio therapy. We developed a functional targeting chemotherapy for transporting drugs across the BBB, destroying VM channels, and eliminating CSCs and cancer cells in the brain. The studies were undertaken on brain glioma cells...
Source: Biomaterials - April 9, 2014 Category: Materials Science Authors: Li XY, Zhao Y, Sun MG, Shi JF, Ju RJ, Zhang CX, Li XT, Zhao WY, Mu LM, Zeng F, Lou JN, Lu WL Tags: Biomaterials Source Type: research
The role of CXCR4 in highly malignant human gliomas biology: Current knowledge and future directions
Given the extensive histomorphological heterogeneity of high‐grade gliomas, in terms of extent of invasiveness, angiogenesis, and necrosis and the poor prognosis for patients despite the advancements made in therapeutic management. The identification of genes associated with these phenotypes will permit a better definition of glioma heterogeneity, which may ultimately lead to better treatment strategies. CXCR4, a cell surface chemokine receptor, is implicated in the growth, invasion, angiogenesis and metastasis in a wide range of malignant tumors, including gliomas. It is overexpressed in glioma cells according to tumor ...
Source: Glia - April 8, 2014 Category: Neurology Authors: Filippo Gagliardi, Ashwin Narayanan, Michele Reni, Alberto Franzin, Elena Mazza, Nicola Boari, Michele Bailo, Paola Zordan, Pietro Mortini Tags: Review Article Source Type: research
In vivo radiation response of proneural glioma [Cell Biology]
Glioblastoma is the most common adult primary brain tumor and has a dismal median survival. Radiation is a mainstay of treatment and significantly improves survival, yet recurrence is nearly inevitable. Better understanding the radiation response of glioblastoma will help improve strategies to treat this devastating disease. Here, we present a... (Source: Proceedings of the National Academy of Sciences)
Source: Proceedings of the National Academy of Sciences - April 8, 2014 Category: Science Authors: Halliday, J., Helmy, K., Pattwell, S. S., Pitter, K. L., LaPlant, Q., Ozawa, T., Holland, E. C. Tags: Biological Sciences Source Type: research
Cover Picture: J. Biophotonics 3–4/2014
Abstract The image graphically describes the use of attenuated total reflection Fourier transform infrared spectroscopy to analyse a component of human blood, serum, in order to diagnose and differentiate patients with high grade gliomas, low grade gliomas and healthy controls. The translation of such a methodology to the clinic would enable earlier detection of brain cancer reducing mortality and morbidity for patients. (Picture: J. R. Hands and M. J. Baker) (Source: Journal of Biophotonics)
Source: Journal of Biophotonics - April 8, 2014 Category: Physics Tags: Cover Picture Source Type: research
Pleiotropic Associations of Risk Variants Identified for Other Cancers With Lung Cancer Risk: The PAGE and TRICL Consortia
Conclusions Our findings demonstrate a novel pleiotropic association between the breast cancer LSP1 risk region marked by variant rs3817198 and lung cancer risk. (Source: JNCI)
Source: JNCI - April 8, 2014 Category: Cancer & Oncology Authors: Park, S. L., Fesinmeyer, M. D., Timofeeva, M., Caberto, C. P., Kocarnik, J. M., Han, Y., Love, S.-A., Young, A., Dumitrescu, L., Lin, Y., Goodloe, R., Wilkens, L. R., Hindorff, L., Fowke, J. H., Carty, C., Buyske, S., Schumacher, F. R., Butler, A., Dilks, Tags: Article Source Type: research
Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.
CONCLUSIONS: A subset of IDH-mutant gliomas with mutations in driver oncogenes has a more malignant phenotype in patients. Identification of these alterations may provide an opportunity for use of targeted therapies in these patients. PMID: 24714777 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 8, 2014 Category: Cancer & Oncology Authors: Wakimoto H, Tanaka S, Curry WT, Loebel F, Zhao D, Tateishi K, Chen J, Klofas LK, Lelic N, Kim JC, Dias-Santagata D, Ellisen LW, Borger DR, Fendt SM, Vander Heiden M, Batchelor TT, Iafrate AJ, Cahill DP, Chi AS Tags: Clin Cancer Res Source Type: research
Reduced phosphorylation of Stat3 at Ser-727 mediated by Casein Kinase 2 - Protein Phosphatase 2A enhances Stat3 Tyr-705 induced tumorigenic potential of glioma cells.
Abstract Signal transducer and activator of transcription 3 (Stat3) is a transcription factor that is involved in cell survival and proliferation and has been found to be persistently activated in most human cancers mainly through its phosphorylation at Tyr-705. However, the role and regulation of Stat3 Ser-727 phosphorylation in cancer cells has not been clearly evaluated. In our findings, correlation studies on expression of CK2 and Stat3 Ser-727 phosphorylation levels in human glioma patient samples as well as rat orthotopic tumor model shows a degree of negative correlation. Moreover, brain tumor cell lines wer...
Source: Cellular Signalling - April 8, 2014 Category: Cytology Authors: Mandal T, Bhowmik A, Chatterjee A, Chatterjee U, Chatterjee S, Ghosh MK Tags: Cell Signal Source Type: research